Entinostat (MS-275) - HDAC Inhibitor. CAS# 209783-80-2 0166 is a novel potent

is a novel potent

NMS-873 provided critical validation of VCP as a cancer target

InChiKey: SHRCVZJKZJGIHQ-UHFFFAOYSA-N

S3I-201 inhibits breast carcinoma MDA-MB-435

complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors

Entinostat (MS-275) - HDAC Inhibitor. CAS# 209783-80-2 0166 is a novel potentEntinostat (MS 275), CAS No. 209783 80 2, is a potent and selective HDAC inhibitor. It inhibits HDAC1 and HDAC3 with IC50 of 0. 51 M and 1. 7 M, but not the other HDACs 4, 6, 8, and 10 (IC50 > 100 M). MS 275 induces accumulation of p21WAF1 CIP1 and gelsolin in K562 cell. It was shown to reduce S phase cells and induce G1 phase cells in A2780 cells. MS 275 shows great inhibition to human leukemia and lymphoma cells, decreases expression of cyclin D1